chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sneezing; extremely congestion; breathing out by my mouth because hard for me to breath; Itchy eyes; Severe runny nose; Sneezing; extremely congestion; breathing out by my mouth because hard for me to breath; Sneezing; extremely congestion; breathing out by my mouth because hard for me to breath; I was tired I could not get out of the bed, I had no energy; Allergy; Tiredness/Feeling so exhausted; Dry mouth; Arm pain; This is a spontaneous report received from a contactable consumer (patient). A 47-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/lot number: EW0171), via an unspecified route of administration, administered in arm right on 21Apr2021 (at the age of 47-year-old) as dose number unknown, single for COVID-19 immunization. The patient medical history was not reported. The patient concomitant medication included ergocalciferol/retinol palmitate (VITAMINS A and D) taken for an unspecified indication. On an unspecified date in Apr2021, the patient experienced allergy, arm pain, tiredness/feeling so exhausted, dry mouth, I was tired I could not get out of the bed, I had no energy. On 24Apr2021, the patient experienced sneezing; extremely congestion; breathing out by my mouth because hard for me to breath, itchy eyes, severe runny nose. Patient stated, she got the shot the COVID shot on Wednesday 21Apr2021, and it was her first. She had allergy go and on pass on a week after the shot, sneezing, congestion and itchy eyes on 24Apr2021, but before the shot she was fine, after receiving the Covid shot she had arm pain for 2 days, for her congestion clear up on second day, her arm pain went away on the third day, she does not had fever. Congestion came back on Friday 23Apr2021 each of these days since she had been taken her first shot. On Saturday 24Apr2021, she woke up extremely congestion and severe runny nose like she used whole toilet paper. She took my Zyrtec (treatment) but she was feeling a little better and she was very tired she could not get out of the bed, she just had no energy, very congested runny nose dry mouth because she was breathing out by my mouth and she had this on and it's hard for her to breathe in. she was breathing but not out of her nose and right now her right nose was little clear but left was till congested, so dry mouth she was breathing out of my mouth but she don't have fever, it's 4 days later, she was feeling it so exhausted. she remembered the first day, it is like a too mild, and then she gets extremely get tired. Patient stated as far as the congestion, I am not feeling that much right now. The patient received Zyrtec as treatment for the events sneezing, extremely congestion. Outcome of all the events was unknown.  No follow up attempts are needed, no further information expected.
Child showed signs of anxiety prior to vaccines so he sat on his guardian's lap, child nervous during vaccines but allowing vaccines without verbal protest. After last vaccine to be given ( Pediatric Pfizer) child in guardians arms lost consciousness for less than 5 seconds,  child slumped in guardians arms, turned pale, loss control of bladder, then came around and began to lift head and stand in guardians arms. Child was able to assist with sitting and laying on stirrup medical bed in room with use of step and assistance of nurse and guardian, child laid down and rested for 10 minutes, was given sips of water and instructed on breathing and after 10 minutes given bite to eat of fruit breakfast bar, child laid back down, instructed to and able to follow commands to pumping hands for increased circulation for approximately 3  minutes. Child stated he was feeling better, child sat up on bed with guardian and nurse present for approximately 10 minutes used distraction conversation with guardian about family child participated and smiled and laughed with conversation, child displayed signs of improvement with conversation, self supporting bodily movements, improved pallor and hands warm to touch.
It's been 31 days since my second dose. I started getting dizzy while sitting and standing; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (It's been 31 days since my second dose. I started getting dizzy while sitting and standing) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history is provided by the reporter.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DIZZINESS (It's been 31 days since my second dose. I started getting dizzy while sitting and standing). At the time of the report, DIZZINESS (It's been 31 days since my second dose. I started getting dizzy while sitting and standing) outcome was unknown.            No treatment medication were provided.  No concomitant medication were provided.
Right leg swelled significantly, particularly at the ankle/Achilles tendon; A spontaneous report was received from a consumer who is a male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced right leg swelled significantly, particularly at the ankle/Achilles tendon/peripheral swelling.   The patient's medical history was not provided. No concomitant medications were reported.  On 05 Jan 2021, the patient received their second of two planned doses of mRNA-1273 (Lot number: not provided) intramuscularly for prophylaxis of COVID-19 infection.   On 06 Jan 2021, the patient reported his right leg swelled up, particularly at the ankle/Achilles and crippled him. He was hospitalized. During his hospitalization the patient had the following tests performed, foot x-ray which showed no damage anatomically and blood work (no results provided).   Treatment for the event included anti-inflammatories.   Action taken with mRNA-1273 in response to the events was not provided.   The outcome of the event, right leg swelled significantly, particularly at the ankle/Achilles tendon/peripheral swelling, was considered not resolved.; Reporter's Comments: This report concerns a male consumer who received Moderna's COVID-19 Vaccine (mRNA-1273), (Lot # not provided), and within 2 days, experienced serious, unlisted, right leg/Achilles tendon/peripheral swelling. Very limited information regarding this event has been provided at this time.  Further information has been requested.
After receiving vaccination Friday afternoon patient awoke on Wednesday with redness and slight swelling on the arm of injection site. Redness was from just below shoulder to elbow.
Red blotches after receiving the booster dose/2 spots at the time/Spots on arms and legs/4-5 little spots in a line/ has on torso back shoulders, besides arms legs; little itchy red spots/4-5 little spots in a line and they itch; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (Red blotches after receiving the booster dose/2 spots at the time/Spots on arms and legs/4-5 little spots in a line/ has on torso back shoulders, besides arms legs) and RASH PRURITIC (little itchy red spots/4-5 little spots in a line and they itch) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 034F21A, 014M20A and 015M20A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy (Penicillin variants), Allergic reaction to analgesics (Tramadol), Food allergy (Garlic), Blood pressure and Arteriosclerosis (plaque on blood). Concomitant products included ATORVASTATIN for Arteriosclerosis, LISINOPRIL for Blood pressure.   On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. In November 2021, the patient experienced RASH MACULAR (Red blotches after receiving the booster dose/2 spots at the time/Spots on arms and legs/4-5 little spots in a line/ has on torso back shoulders, besides arms legs) and RASH PRURITIC (little itchy red spots/4-5 little spots in a line and they itch). At the time of the report, RASH MACULAR (Red blotches after receiving the booster dose/2 spots at the time/Spots on arms and legs/4-5 little spots in a line/ has on torso back shoulders, besides arms legs) and RASH PRURITIC (little itchy red spots/4-5 little spots in a line and they itch) had not resolved.            Patient does not had tested positive for COVID and does not had similar events in the past.  It was reported that after using steroids, the red spots became large. Two days after receiving the booster dose, patient started to experience the adverse reactions. Patient went to his Doctor first and he referred him to a dermatologist, he's been visiting him since December.  Patient took 2 series of Steroids as treatment. With treatment (steroids), the adverse event has improved but If patient stops taking steroids the blotches comes back.
Patient received the vaccine around 11 am.  He hadn't been feeling well (headache, dizziness) per report and initially called in to work.  He then decided to come to work and was found down in a patient bathroom during his shift on our Facility while taking care of a patient (he was a nurse aid).  Patient was coded and the team and was transferred to our Facility ED.   He expired 3/3 2112
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 74-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 17Sep2022 at 10:30 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 74 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Diabetes" (unspecified if ongoing); "High blood pressure" (unspecified if ongoing); "High cholesterol" (unspecified if ongoing). The patient had no known allergies. There were no concomitant medications. The patient did not receive other medications in 2 weeks.  The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Oct2022, outcome "unknown" and all described as "Treatment of COVID-19". The patient tested positive on an unspecified date in Oct2022. The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (Oct2022) Positive. Therapeutic measures were taken as a result of covid-19 which included Paxlovid.   The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
I ended up testing positive with strep six days after my 2nd shot. All of the Covid and flu tests were negative(also tested six days after shot).  I was given ammox and am no longer suffering from strep.   I have a strange pain in the opposite side of my neck/shoulder that I cant get to go away. It started after my first shot, then went away after the first night, but it has stuck around since my second shot. Not extreme pain, but it is hard to stay sleeping. My arm will go numb if I sleep on that side. Very annoying. The right side of my chest gets cramped now and again.   I am not sure if any of this is related to the shot, but I did not know it before getting it.
High fever. Chills/aching. Leg Cramps. Sore arm.
shingles; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team, Program ID: The reporter is the patient.  An 82-year-old female patient received BNT162b2 (BNT162B2), in 2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary immunization series complete, MANUFACTURER UNKNOWN), administration date: 2020, for COVID-19 immunization. The following information was reported: HERPES ZOSTER (non-serious) with onset 2021, outcome "unknown", described as "shingles".  Additional information: Caller clarifies she has had both Covid 19 vaccine primary doses in 2020 and one booster in 2021. In 2022 she did not get her second booster. She had shingles that year and different stuff going on so she did not get the second booster. This year, she went to get the second booster at (Facility name) and they were no longer giving it. They have moved on to the latest shot Pfizer has out. Wanted to know if she could skip the second booster or does she need to get it?   The information on the batch/lot number for [BNT162B2] has been requested and will be submitted if and when received
Initial report received on 02 March 2007 from a physician. A 53-year-old female patient with a past medical history of allergies and asthma, had received a dose of Tetanus Adsorbed Preservative-free, lot number U1624AB, on 19 January 2007. The expiration date of the vaccine was reported as 13 December 2007. The route and site if administration were not provided. Two days post-immunization, the patient developed a rash (area not reported). Treatments received and diagnostic testing's performed were not reported. 21 days post-immunization, the patient was evaluated by her physician for mono neuropathies of the jaw. During physical examination it was noted that the patient was not able to stick her tongue out of her mouth and she "had left eye droop". The patient was treated with steroids with some improvement in her symptoms. At the time of this report, it was unknown if the patient had recovered. Additional information was received from a physician on 06 March 2006 and has been added to this initial version. The patient developed a fine whole body rash on 22 January 2007. She had malaise and a fever. On 09 February 2007, the patient developed facial muscle spasms. She reported that "the masseter and pterygoid muscles are so spasmed and constantly painful that I cannot open my mouth more than 1 cm". Additional symptoms included an "intolerable" headache and left eye swelling and drooping. She can only consume liquids. The patient is a dentist and has been unable to work for three weeks. Per the reporting physician, the patient had trismus and encephalopathy. As of 06 March 2007, the encephalopathy had cleared, but the trismus was only 30% improved. She had not recovered at the time of this report.
Anatomical site of injection: her left elbow; when patient received the second vaccine dose, she sometimes like "bleed"; This is a spontaneous report from a contactable consumer via the Pfizer-sponsored Program, a Regulatory Authority. A 62-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) intramuscularly, administered in the left elbow(pending clarification) on 08Jul2021 (batch/lot number: FA6780 and expiration date: 30Jul2021) at 62 years old as DOSE 2, SINGLE for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. It was unknown if patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162B2 intramuscularly, administered in the left elbow on 14Jun2021 (batch/lot number and expiration date were unknown) at 62 years old, as DOSE 1, SINGLE for COVID-19 immunization and experienced hematoma in the area of administration. It was reported that when patient received the second vaccine dose, she sometimes like "bleed' (vaccination site bleeding) since an unknown date in Jul2021. Reporter stated, "you inject, obviously you use needle and so apparently patient has like hematoma." The reporter did not see it and the other problem was, patient was not present during the call. Reporter had not seen if patient was developing a hematoma. But, the nurse of 40 years, in the summary thoughts, was wondering, If the vaccine did not go into the vein therefore was not effective because it did not land in the muscles or should she get another vaccine. Patient wanted to know if she can get another vaccine. She felt like, if it did go into the veins instead of muscles and therefore, she wanted to get another vaccine. The outcome of the event "she sometimes like "bleed' (vaccination site bleeding)" was unknown.   Follow-up attempts are completed. No further information is expected.
No adverse effect; Improperly stored dose of VARIVAX; This spontaneous report was received from a nurse refers to a patient of unknown age and gender.  The patient's medical history, concurrent conditions, past drugs and allergies were unknown. Concomitant therapies included sterile diluent.  On 12-AUG-2019, the patient was vaccinated with one improperly stored dose (product storage error) of varicella virus vaccine live (oka/merck) (VARIVAX) (lot # R027995 and expiration date: 01-OCT-2020) for prophylaxis. No adverse effects were reported. The sterile diluent that was used to reconstitute the varicella virus vaccine live (oka/merck) (VARIVAX) was stored properly. The temperature excursion was seen at temperature of 6-degree Fahrenheit to 14-degree Fahrenheit (7.5 F) for 30 minutes. Previous temperature excursion was noted at temperature of 6-degree Fahrenheit to 14-degree Fahrenheit (10 F) for 28 minutes. This call was because of digital data logger. The outcome of product storage error was unknown.
Red rash noted on neck. No symptoms associated with rash. Digital photos taken. PT unsure if rash present before vaccination.
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-Mar-2022; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-Mar-2022; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-Mar-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-Mar-2022) in a 19-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Mar-2022 at 2:21 PM, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 28-Mar-2022 at 2:21 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-Mar-2022). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-Mar-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-Mar-2022) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 28-Mar-2022) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. It was reported that patient had received lot 066H21A past its 30 days expiry date. No treatment medications were reported.   This case was linked to MOD-2022-542869 (Patient Link).
Next day - achy back. Two days later - tingly, itchy face. Slight flu-like sx - runny nose, sore throat.
This spontaneous report as received from a pharmacy student refers to a patient of unknown age and gender. The patient's medical history was not reported. On 21-JUL-2016, the patient was vaccinated with an expired dose of ZOSTAVAX (lot # K008079, expiration date 03-SEP-2015)(dose, route and site of administration were not reported). Concomitant medications were not reported. No adverse symptoms were reported. Additional information has been requested.
Fatigue, low grade fever, lump under my armpit and rash at injection site.
Patient is fully vaccinated. Hospitalized due to Covid.  Patient caught Covid from her daughter who she lives with. Patient has been in the hospital since 8/20.
Donor states hip pain since 2nd rabies vaccine on 210/08. States onset approx 3 hours after injection and today (2/11/08) feels hips are popping out of place. Reaction marked yes by medical receptionist and referred. While general aches and muscle pain are known reactions to vaccinations, localized pain is not a recognized reaction after vaccines.
Patient was seen on 12/18/2015 and was given a PCV13 vaccine. Pt tolerated well. Patient stated approx. an hour later at home she started to develop pain in her right arm. States it began to swell and had redness. Pt then waited and cane into Urgent Care on 12/22/2015 after developing a fever. She had erythema and early blistering over 10x20 cm area with increased warmth. She was given pain meds. Her WBC was high. She was  given IV Fluids for her fever and discharged home using cool compresses and cortisone cream. Pt then followed up with PCP on 12/23/2015 and 12/28/2015. Visit on 12/28/2015 stated it was starting to improve. Pt still had redness and pain. Pt states she had PNEUMOVAX 23 in past and she never had a reaction to that vaccine.
pt was 39 weeks and 4 days pregnant. mild pregnancy-induced hypertension at end of pregnancy. Induced labor. Delivered on 08/19/2021, viable newborn weighed 7lb 8oz. Pt had abnormal/prolonged bleeding after IV stick, epidural placement, and post partum/post-delivery. Difficulty controlling bleeding from epidural sight even with continuous applied pressure. Heavy post partum bleeding requiring  multi-drug therapy and manual clot extraction to control bleeding.
Diffuse maculopapular rash on trunk and extremities, low grade fever 100.4
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 44-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 19Nov2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 43 years, in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Narcolepsy" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "recovered" (2023) and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (17Jul2023) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300253699 same reporter/patient, different product/AE;
pt did not have a reaction to this vaccine. Pt was given a vaccine that was beyond use of refrigeration. Lot number was not expired.